PerkinElmer

The companies will incorporate PerkinElmer's LabChip GX Touch nucleic acid analyzer in the upfront workflow of Agena's MassArray system.

Revenues from the company's diagnostics business and discovery and analytical solutions business each grew 10 percent on an organic basis.

PerkinElmer will offer providers and patients screening for ASAH1 mutations through its PerkinElmer Genomics laboratory unit.

The partners will test PerkinElmer's Vanadis NIPT platform on samples from 2,650 women to determine detection and false positive rates.

Illumina has extended a supply agreement with Foundation until 2023 and developed an automated metagenomics workflow with PerkinElmer.

The company said revenues in its diagnostics business unit rose 62 percent during the quarter.

PerkinElmer is working on an app that reports pathogenic or likely pathogenic ACMG-59 genetic variants, and NorthShore's app will report a prostate cancer risk score.